CRDF
HealthcareCardiff Oncology, Inc.
$2.84
+$0.18 (+6.77%)
Jan 5, 2026
Price History (1Y)
Analysis
Cardiff Oncology, Inc. (CRDF) operates in the healthcare sector within the biotechnology industry. The company has a relatively small scale, with 32 employees, and a market capitalization of $191.30 million. Its revenue for the trailing twelve months is $501,000. The company's financial health is concerning, with significant losses. Net income for the TTM was -$50,446,000, while EBITDA was -$53,333,000. Free cash flow was also negative at -$24,983,624. However, the company does have a substantial amount of cash on hand, totaling $60.59 million. The debt-to-equity ratio is 2.07. The valuation context for Cardiff Oncology, Inc. (CRDF) is challenging. The forward P/E ratio is -3.69 and the price to sales ratio is 381.84. Revenue growth has been negative year-over-year at -27.3%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Visit website →Key Statistics
- Market Cap
- $191.30M
- P/E Ratio
- N/A
- 52-Week High
- $4.99
- 52-Week Low
- $1.90
- Avg Volume
- 883.13K
- Beta
- 1.40
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 32